Lupin announces presentation of phase 1 data on LNP7457 (PRMT5 inhibitor) at the ASCO – Annual… EP News Bureau May 27, 2025 Current data from Lupin indicates that LNP7457 is unique within its field and appears to be safe and well-tolerated as a…
